These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

864 related items for PubMed ID: 28639894

  • 1. Deregulated expression of Cdc6 as BCR/ABL-dependent survival factor in chronic myeloid leukemia cells.
    Zhang JH, He YL, Zhu R, Du W, Xiao JH.
    Tumour Biol; 2017 Jun; 39(6):1010428317713394. PubMed ID: 28639894
    [Abstract] [Full Text] [Related]

  • 2. Study on the treatment of the p15 gene combined with Bcr-abl-specific siRNA and STI571 for chronic myeloid leukemia.
    Wang W, Du Y, Li NN, Lv FF, Lin GQ.
    Genet Mol Res; 2014 May 30; 13(2):4089-101. PubMed ID: 24938701
    [Abstract] [Full Text] [Related]

  • 3. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
    Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, Akgul C, Derdak S, Pickl WF, Wacheck V, Selzer E, Monia BP, Moriggl R, Valent P, Sillaber C.
    Blood; 2005 Apr 15; 105(8):3303-11. PubMed ID: 15626746
    [Abstract] [Full Text] [Related]

  • 4. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
    Liao HF, Su YC, Zheng ZY, Jhih Cai C, Hou MH, Chao KS, Chen YJ.
    Biomed Pharmacother; 2012 Jul 15; 66(5):378-83. PubMed ID: 22397755
    [Abstract] [Full Text] [Related]

  • 5. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
    Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P, Grant S.
    Cancer Res; 2002 Jan 01; 62(1):188-99. PubMed ID: 11782377
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ.
    Blood; 2004 Oct 15; 104(8):2532-9. PubMed ID: 15256422
    [Abstract] [Full Text] [Related]

  • 7. Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells.
    Huang Q, Yang Y, Li X, Huang S.
    Tumour Biol; 2011 Dec 15; 32(6):1191-7. PubMed ID: 21892628
    [Abstract] [Full Text] [Related]

  • 8. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
    Gleixner KV, Ferenc V, Peter B, Gruze A, Meyer RA, Hadzijusufovic E, Cerny-Reiterer S, Mayerhofer M, Pickl WF, Sillaber C, Valent P.
    Cancer Res; 2010 Feb 15; 70(4):1513-23. PubMed ID: 20145140
    [Abstract] [Full Text] [Related]

  • 9. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
    Yu C, Rahmani M, Almenara J, Subler M, Krystal G, Conrad D, Varticovski L, Dent P, Grant S.
    Cancer Res; 2003 May 01; 63(9):2118-26. PubMed ID: 12727828
    [Abstract] [Full Text] [Related]

  • 10. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
    Dai Y, Rahmani M, Pei XY, Dent P, Grant S.
    Blood; 2004 Jul 15; 104(2):509-18. PubMed ID: 15039284
    [Abstract] [Full Text] [Related]

  • 11. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.
    Aichberger KJ, Mayerhofer M, Krauth MT, Vales A, Kondo R, Derdak S, Pickl WF, Selzer E, Deininger M, Druker BJ, Sillaber C, Esterbauer H, Valent P.
    Cancer Res; 2005 Oct 15; 65(20):9436-44. PubMed ID: 16230407
    [Abstract] [Full Text] [Related]

  • 12. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M, Nguyen TK, Dent P, Grant S.
    Mol Pharmacol; 2007 Sep 15; 72(3):788-95. PubMed ID: 17595328
    [Abstract] [Full Text] [Related]

  • 13. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
    Yu C, Krystal G, Dent P, Grant S.
    Clin Cancer Res; 2002 Sep 15; 8(9):2976-84. PubMed ID: 12231544
    [Abstract] [Full Text] [Related]

  • 14. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
    Grimaudo S, Meli M, Di Cristina A, Ferro A, Pipitone MR, Romagnoli R, Simoni D, Dieli F, Tolomeo M.
    Anticancer Drugs; 2013 Apr 15; 24(4):384-93. PubMed ID: 23370613
    [Abstract] [Full Text] [Related]

  • 15. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.
    Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M.
    Blood; 2003 Jan 15; 101(2):690-8. PubMed ID: 12509383
    [Abstract] [Full Text] [Related]

  • 16. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE.
    Oncogene; 2002 Nov 21; 21(53):8075-88. PubMed ID: 12444544
    [Abstract] [Full Text] [Related]

  • 17. Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells.
    Kawauchi K, Ogasawara T, Yasuyama M, Ohkawa Si.
    Blood Cells Mol Dis; 2003 Nov 21; 31(1):11-7. PubMed ID: 12850478
    [Abstract] [Full Text] [Related]

  • 18. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, Tepperberg J, Jove R, Bhalla K.
    Cancer Res; 2002 Oct 15; 62(20):5761-9. PubMed ID: 12384536
    [Abstract] [Full Text] [Related]

  • 19. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X, Zhao H, Li Y, Fan J, Sun Y, Wang S, Wang Z, Song P, Ju D.
    Autophagy; 2015 Oct 15; 11(2):355-72. PubMed ID: 25701353
    [Abstract] [Full Text] [Related]

  • 20. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
    Oetzel C, Jonuleit T, Götz A, van der Kuip H, Michels H, Duyster J, Hallek M, Aulitzky WE.
    Clin Cancer Res; 2000 May 15; 6(5):1958-68. PubMed ID: 10815921
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.